Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 177

1.

Inflatable penile prosthesis implantation after gender affirming phalloplasty with radial forearm free flap.

Kocjancic E, Jaunarena JH, Schechter L, Acar Ö.

Int J Impot Res. 2019 Jun 6. doi: 10.1038/s41443-019-0153-8. [Epub ahead of print] Review.

PMID:
31171852
2.

Training Surgeons in Gender Confirmation Surgery.

Schechter LS, Schechter RB.

J Craniofac Surg. 2019 Apr 4. doi: 10.1097/SCS.0000000000005477. [Epub ahead of print]

PMID:
31033767
3.

Subsidies versus mental accounting nudges: Harnessing mobile payment systems to improve sanitation.

Lipscomb M, Schechter L.

J Dev Econ. 2018 Nov;135:235-254. doi: 10.1016/j.jdeveco.2018.07.007.

4.

Cheek Augmentation Techniques.

Whitehead DM, Schechter LS.

Facial Plast Surg Clin North Am. 2019 May;27(2):199-206. doi: 10.1016/j.fsc.2018.12.003. Epub 2019 Mar 2. Review.

PMID:
30940385
5.

Gender Confirmation Surgery: Moving Forward.

Schechter LS, Cohen M.

J Craniofac Surg. 2019 Mar 19. doi: 10.1097/SCS.0000000000005456. [Epub ahead of print]

PMID:
30896518
6.

Receptiveness to advice, cognitive ability, and technology adoption.

Barham BL, Chavas JP, Fitz D, Schechter L.

J Econ Behav Organ. 2018 May;149:239-268. doi: 10.1016/j.jebo.2017.12.025. Epub 2018 Apr 16.

7.

Gender Surgery: A Truly Multidisciplinary Field.

Schechter LS, Safa B.

Clin Plast Surg. 2018 Jul;45(3):xiii. doi: 10.1016/j.cps.2018.05.001. No abstract available.

PMID:
29908634
8.

Introduction to Phalloplasty.

Schechter LS, Safa B.

Clin Plast Surg. 2018 Jul;45(3):387-389. doi: 10.1016/j.cps.2018.03.014. Epub 2018 May 1. Review.

PMID:
29908627
9.

Extensive Gene Amplification as a Mechanism for Piperacillin-Tazobactam Resistance in Escherichia coli.

Schechter LM, Creely DP, Garner CD, Shortridge D, Nguyen H, Chen L, Hanson BM, Sodergren E, Weinstock GM, Dunne WM Jr, van Belkum A, Leopold SR.

MBio. 2018 Apr 24;9(2). pii: e00583-18. doi: 10.1128/mBio.00583-18.

10.

Gender Affirmation: Medical & Surgical Perspectives.

Schechter LS.

Plast Reconstr Surg. 2017 Nov;140(5):1077. doi: 10.1097/PRS.0000000000003824. No abstract available.

PMID:
29068949
11.

Response to Letter to the Editor: "Gender Confirmation Surgery: Guiding Principles".

Schechter LS.

J Sex Med. 2017 Aug;14(8):1067. doi: 10.1016/j.jsxm.2017.06.002. No abstract available.

PMID:
28760249
12.

Gender Confirmation Surgery and Terminology in Transgender Health-Reply.

Berli JU, Knudson G, Schechter L.

JAMA Surg. 2017 Nov 1;152(11):1091. doi: 10.1001/jamasurg.2017.2347. No abstract available.

PMID:
28724140
13.

Perceptions of Success in Bariatric Surgery: a Nationwide Survey Among Medical Professionals.

Sherf-Dagan S, Schechter L, Lapidus R, Sakran N, Goitein D, Raziel A.

Obes Surg. 2018 Jan;28(1):135-141. doi: 10.1007/s11695-017-2800-9.

PMID:
28695458
14.

Gender Confirmation Surgery: Guiding Principles.

Schechter LS, D'Arpa S, Cohen MN, Kocjancic E, Claes KEY, Monstrey S.

J Sex Med. 2017 Jun;14(6):852-856. doi: 10.1016/j.jsxm.2017.04.001. Epub 2017 May 3.

PMID:
28479133
15.

What Surgeons Need to Know About Gender Confirmation Surgery When Providing Care for Transgender Individuals: A Review.

Berli JU, Knudson G, Fraser L, Tangpricha V, Ettner R, Ettner FM, Safer JD, Graham J, Monstrey S, Schechter L.

JAMA Surg. 2017 Apr 1;152(4):394-400. doi: 10.1001/jamasurg.2016.5549. Review.

PMID:
28196182
16.

Gender Confirmation Surgery: A New Frontier in Plastic Surgery Education.

Schechter LS, Cohen M.

Plast Reconstr Surg. 2016 Oct;138(4):784e-5e. doi: 10.1097/PRS.0000000000002594. No abstract available.

PMID:
27314940
17.

Gender Confirmation Surgery: An Update for the Primary Care Provider.

Schechter LS.

Transgend Health. 2016 Jan 1;1(1):32-40. doi: 10.1089/trgh.2015.0006. eCollection 2016. Review.

18.

Stability of Experimental and Survey Measures of Risk, Time, and Social Preferences: A Review and Some New Results.

Chuang Y, Schechter L.

J Dev Econ. 2015 Nov;117:151-170. doi: 10.1016/j.jdeveco.2015.07.008. Epub 2015 Aug 19.

19.

"NACsomes": A new classification system of the blood supply to the nipple areola complex (NAC) based on diagnostic breast MRI exams.

Seitz IA, Nixon AT, Friedewald SM, Rimler JC, Schechter LS.

J Plast Reconstr Aesthet Surg. 2015 Jun;68(6):792-9. doi: 10.1016/j.bjps.2015.02.027. Epub 2015 Feb 19.

PMID:
25733199
20.

Unusual sequela from a pencil stab wound reveals a retained graphite foreign body.

Seitz IA, Silva BA, Schechter LS.

Pediatr Emerg Care. 2014 Aug;30(8):568-70. doi: 10.1097/PEC.0000000000000192.

PMID:
25098803
21.

The effects of systemic and local microinjection into the central nervous system of the selective serotonin 5-HT6 receptor agonist WAY-208466 on sleep and wakefulness in the rat.

Monti JM, Jantos H, Schechter LE.

Behav Brain Res. 2013 Jul 15;249:65-74. doi: 10.1016/j.bbr.2013.04.024. Epub 2013 Apr 24.

PMID:
23624323
22.
23.

Carbon source and cell density-dependent regulation of type III secretion system gene expression in Pseudomonas syringae pathovar tomato DC3000.

Stauber JL, Loginicheva E, Schechter LM.

Res Microbiol. 2012 Sep-Oct;163(8):531-9. doi: 10.1016/j.resmic.2012.08.005. Epub 2012 Aug 23.

PMID:
22944041
24.

Evidence-based practices for thromboembolism prevention: summary of the ASPS Venous Thromboembolism Task Force Report.

Murphy RX Jr, Alderman A, Gutowski K, Kerrigan C, Rosolowski K, Schechter L, Schmitz D, Wilkins E.

Plast Reconstr Surg. 2012 Jul;130(1):168e-175e. doi: 10.1097/PRS.0b013e318254b4ee. Review.

PMID:
22743901
25.

Functional and computational analysis of amino acid patterns predictive of type III secretion system substrates in Pseudomonas syringae.

Schechter LM, Valenta JC, Schneider DJ, Collmer A, Sakk E.

PLoS One. 2012;7(4):e36038. doi: 10.1371/journal.pone.0036038. Epub 2012 Apr 27.

26.

Negative allosteric modulation of metabotropic glutamate receptor 5 results in broad spectrum activity relevant to treatment resistant depression.

Hughes ZA, Neal SJ, Smith DL, Sukoff Rizzo SJ, Pulicicchio CM, Lotarski S, Lu S, Dwyer JM, Brennan J, Olsen M, Bender CN, Kouranova E, Andree TH, Harrison JE, Whiteside GT, Springer D, O'Neil SV, Leonard SK, Schechter LE, Dunlop J, Rosenzweig-Lipson S, Ring RH.

Neuropharmacology. 2013 Mar;66:202-14. doi: 10.1016/j.neuropharm.2012.04.007. Epub 2012 Apr 21.

PMID:
22551786
27.

Concomitant blockade of 5-HT(1A) receptor and 5-HT transporter: use of the Hunter Serotonin toxicity criteria in a clinical pharmacology study.

Parks V, Philipp AW, Raje S, Plotka A, Schechter LE, Connell J, Chalon S.

Eur Neuropsychopharmacol. 2012 Feb;22(2):92-9. doi: 10.1016/j.euroneuro.2011.06.002. Epub 2011 Jul 5.

PMID:
21733663
28.

Characterization of vabicaserin (SCA-136), a selective 5-hydroxytryptamine 2C receptor agonist.

Dunlop J, Watts SW, Barrett JE, Coupet J, Harrison B, Mazandarani H, Nawoschik S, Pangalos MN, Ramamoorthy S, Schechter L, Smith D, Stack G, Zhang J, Zhang G, Rosenzweig-Lipson S.

J Pharmacol Exp Ther. 2011 Jun;337(3):673-80. doi: 10.1124/jpet.111.179572. Epub 2011 Mar 14.

PMID:
21402690
29.
30.

Identification of 3-sulfonylindazole derivatives as potent and selective 5-HT(6) antagonists.

Liu KG, Robichaud AJ, Greenfield AA, Lo JR, Grosanu C, Mattes JF, Cai Y, Zhang GM, Zhang JY, Kowal DM, Smith DL, Di L, Kerns EH, Schechter LE, Comery TA.

Bioorg Med Chem. 2011 Jan 1;19(1):650-62. doi: 10.1016/j.bmc.2010.10.033. Epub 2010 Oct 20.

PMID:
21093272
31.

5-Piperazinyl-3-sulfonylindazoles as potent and selective 5-hydroxytryptamine-6 antagonists.

Liu KG, Robichaud AJ, Bernotas RC, Yan Y, Lo JR, Zhang MY, Hughes ZA, Huselton C, Zhang GM, Zhang JY, Kowal DM, Smith DL, Schechter LE, Comery TA.

J Med Chem. 2010 Nov 11;53(21):7639-46. doi: 10.1021/jm1007825.

PMID:
20932009
32.

Evidence-based patient safety advisory: blood dyscrasias.

Haeck PC, Swanson JA, Schechter LS, Hall-Findlay EJ, McDevitt NB, Smotrich GA, Reisman NR, Glasberg SB; ASPS Patient Safety Committee.

Plast Reconstr Surg. 2009 Oct;124(4 Suppl):82S-95S. doi: 10.1097/PRS.0b013e3181b54640. Review.

PMID:
20827242
33.

Evidence-based patient safety advisory: patient selection and procedures in ambulatory surgery.

Haeck PC, Swanson JA, Iverson RE, Schechter LS, Singer R, Basu CB, Damitz LA, Glasberg SB, Glassman LS, McGuire MF; ASPS Patient Safety Committee.

Plast Reconstr Surg. 2009 Oct;124(4 Suppl):6S-27S. doi: 10.1097/PRS.0b013e3181b8e880. Review.

PMID:
20827237
34.

Translocation of NopP by Sinorhizobium fredii USDA257 into Vigna unguiculata root nodules.

Schechter LM, Guenther J, Olcay EA, Jang S, Krishnan HB.

Appl Environ Microbiol. 2010 Jun;76(11):3758-61. doi: 10.1128/AEM.03122-09. Epub 2010 Apr 9.

35.

Angiotensin IV elevates oxytocin levels in the rat amygdala and produces anxiolytic-like activity through subsequent oxytocin receptor activation.

Beyer CE, Dwyer JM, Platt BJ, Neal S, Luo B, Ling HP, Lin Q, Mark RJ, Rosenzweig-Lipson S, Schechter LE.

Psychopharmacology (Berl). 2010 May;209(4):303-11. doi: 10.1007/s00213-010-1791-1. Epub 2010 Mar 12.

PMID:
20224888
36.

Antidepressant and anxiolytic effects of selective 5-HT6 receptor agonists in rats.

Carr GV, Schechter LE, Lucki I.

Psychopharmacology (Berl). 2011 Feb;213(2-3):499-507. doi: 10.1007/s00213-010-1798-7. Epub 2010 Mar 9.

37.

Facilitating harvest of the serratus fascial flap with ultrasonic dissection.

Seitz IA, Williams C, Schechter LS.

Eplasty. 2010 Feb 23;10:e18.

38.

Anatomy of a medication error: inadvertent subcutaneous injection of neosynephrine during nasal surgery.

Seitz IA, Tojo D, Schechter LS.

Plast Reconstr Surg. 2010 Mar;125(3):113e-4e. doi: 10.1097/PRS.0b013e3181cb68f9. No abstract available.

PMID:
20195091
39.

Acute lecozotan administration increases learning and memory in rats without affecting anxiety or behavioral depression.

Skirzewski M, Hernandez L, Schechter LE, Rada P.

Pharmacol Biochem Behav. 2010 May;95(3):325-30. doi: 10.1016/j.pbb.2010.02.008. Epub 2010 Feb 17.

PMID:
20170670
40.

5-Cyclic amine-3-arylsulfonylindazoles as novel 5-HT6 receptor antagonists.

Haydar SN, Yun H, Andrae PM, Mattes J, Zhang J, Kramer A, Smith DL, Huselton C, Graf R, Aschmies S, Schechter LE, Comery TA, Robichaud AJ.

J Med Chem. 2010 Mar 25;53(6):2521-7. doi: 10.1021/jm901674f.

PMID:
20170099
41.

3-(Arylsulfonyl)-1-(azacyclyl)-1H-indoles are 5-HT(6) receptor modulators.

Bernotas RC, Antane S, Shenoy R, Le VD, Chen P, Harrison BL, Robichaud AJ, Zhang GM, Smith D, Schechter LE.

Bioorg Med Chem Lett. 2010 Mar 1;20(5):1657-60. doi: 10.1016/j.bmcl.2010.01.073. Epub 2010 Jan 21.

PMID:
20138763
42.

Novel benzofuran derivatives with dual 5-HT1A receptor and serotonin transporter affinity.

Venkatesan AM, Dos Santos O, Ellingboe J, Evrard DA, Harrison BL, Smith DL, Scerni R, Hornby GA, Schechter LE, Andree TH.

Bioorg Med Chem Lett. 2010 Feb 1;20(3):824-7. doi: 10.1016/j.bmcl.2009.12.093. Epub 2010 Jan 4.

PMID:
20064720
43.

Preclinical characterization of BRL 44408: antidepressant- and analgesic-like activity through selective alpha2A-adrenoceptor antagonism.

Dwyer JM, Platt BJ, Rizzo SJ, Pulicicchio CM, Wantuch C, Zhang MY, Cummons T, Leventhal L, Bender CN, Zhang J, Kowal D, Lu S, Rajarao SJ, Smith DL, Shilling AD, Wang J, Butera J, Resnick L, Rosenzweig-Lipson S, Schechter LE, Beyer CE.

Int J Neuropsychopharmacol. 2010 Oct;13(9):1193-205. doi: 10.1017/S1461145709991088. Epub 2010 Jan 5.

PMID:
20047711
44.

Synthesis and structure-activity relationship of novel lactam-fused chroman derivatives having dual affinity at the 5-HT(1A) receptor and the serotonin transporter.

Shen Z, Siva Ramamoorthy P, Hatzenbuhler NT, Evrard DA, Childers W, Harrison BL, Chlenov M, Hornby G, Smith DL, Sullivan KM, Schechter LE, Andree TH.

Bioorg Med Chem Lett. 2010 Jan 1;20(1):222-7. doi: 10.1016/j.bmcl.2009.10.134. Epub 2009 Oct 31.

PMID:
19932965
45.

1-(2-Aminoethyl)-3-(arylsulfonyl)-1H-pyrrolopyridines are 5-HT(6) receptor ligands.

Bernotas RC, Antane SA, Lenicek SE, Haydar SN, Robichaud AJ, Harrison BL, Zhang GM, Smith D, Coupet J, Schechter LE.

Bioorg Med Chem Lett. 2009 Dec 15;19(24):6935-8. doi: 10.1016/j.bmcl.2009.10.067. Epub 2009 Oct 20.

PMID:
19884004
46.

Synthesis, potency, and in vivo evaluation of 2-piperazin-1-ylquinoline analogues as dual serotonin reuptake inhibitors and serotonin 5-HT1A receptor antagonists.

Zhou D, Stack GP, Lo J, Failli AA, Evrard DA, Harrison BL, Hatzenbuhler NT, Tran M, Croce S, Yi S, Golembieski J, Hornby GA, Lai M, Lin Q, Schechter LE, Smith DL, Shilling AD, Huselton C, Mitchell P, Beyer CE, Andree TH.

J Med Chem. 2009 Aug 13;52(15):4955-9. doi: 10.1021/jm900374r.

PMID:
19719241
47.

Receptor and behavioral pharmacology of WAY-267464, a non-peptide oxytocin receptor agonist.

Ring RH, Schechter LE, Leonard SK, Dwyer JM, Platt BJ, Graf R, Grauer S, Pulicicchio C, Resnick L, Rahman Z, Sukoff Rizzo SJ, Luo B, Beyer CE, Logue SF, Marquis KL, Hughes ZA, Rosenzweig-Lipson S.

Neuropharmacology. 2010 Jan;58(1):69-77. doi: 10.1016/j.neuropharm.2009.07.016. Epub 2009 Jul 15.

PMID:
19615387
49.

Novel 1-aminoethyl-3-arylsulfonyl-1H-pyrrolo[2,3-b]pyridines are potent 5-HT(6) agonists.

Bernotas RC, Lenicek S, Antane S, Cole DC, Harrison BL, Robichaud AJ, Zhang GM, Smith D, Platt B, Lin Q, Li P, Coupet J, Rosenzweig-Lipson S, Beyer CE, Schechter LE.

Bioorg Med Chem. 2009 Jul 15;17(14):5153-63. doi: 10.1016/j.bmc.2009.05.055. Epub 2009 May 29.

PMID:
19523834
50.

5-HT(1A) receptor antagonism reverses and prevents fluoxetine-induced sexual dysfunction in rats.

Sukoff Rizzo SJ, Pulicicchio C, Malberg JE, Andree TH, Stack GP, Hughes ZA, Schechter LE, Rosenzweig-Lipson S.

Int J Neuropsychopharmacol. 2009 Sep;12(8):1045-53. doi: 10.1017/S1461145709000406. Epub 2009 May 13.

PMID:
19435548

Supplemental Content

Loading ...
Support Center